VISCHER advises Oculis on its follow-on public offering
Oculis Holding, a global biopharmaceutical company purposefully driven to save sight and improve eye care, has placed a follow-on public offering of 3.5m ordinary shares at a public offering price of USD 11.50 per ordinary share, for gross proceeds of USD 40.25m, before deducting underwriting discounts and commissions and offering expenses.
The company intends to use the net proceeds from this offering to advance its development programs in Diabetic Macular Edema and other ophthalmic indications, and for working capital and general corporate purposes.
VISCHER has been representing Oculis Holding in this offering for Swiss legal matters with partner Matthias Staehelin (pictured), associates Balthasar Müller, Timothy Woodtli and junior associate Natacha Tang (all corporate/m&a) as well as partner Nadia Tarolli Schmidt and managing associate Adrian Briner (both tax).
